Stocktoria
REGENERON PHARMACEUTICALS, INC. REGN
REGENERON PHARMACEUTICALS, INC. (REGN) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.56% (safety: safe). FY2025 revenue was $14.3B at a 31.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-03 | Citigroup | Neutral (main) |
| 2026-08-03 | Guggenheim | Buy (main) |
| 2026-07-31 | RBC Capital | Sector Perform (main) |
| 2026-07-31 | Morgan Stanley | Equal-Weight (main) |
| 2026-07-31 | Cantor Fitzgerald | Overweight (main) |
| 2026-07-31 | Wells Fargo | Equal-Weight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.337 |
| Retained earnings / assets | 0.883 |
| EBIT / assets | 0.088 |
| Equity / liabilities | 3.36 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| REGN | REGENERON PHARMACEUTICALS, INC. | 5/9 | 9.21 | 14.7 | +1% |
| VTRS | Viatris Inc | 3/9 | 0.65 | — | -3% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | 4/9 | 7.5 | 29.1 | +8.9% |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | 7/9 | -0.41 | 84.8 | +4.3% |
| UPC | Universe Pharmaceuticals INC | 4/9 | 7.37 | — | -22.4% |
| BHC | Bausch Health Companies Inc. | 7/9 | -0.26 | 17.8 | +6.7% |
| ZTS | Zoetis Inc. | 5/9 | — | 12.4 | +2.3% |
About REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
FAQ
Is REGN financially healthy?
REGENERON PHARMACEUTICALS, INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does REGN pay a dividend, and is it safe?
Yes. REGENERON PHARMACEUTICALS, INC. pays a dividend yielding about 0.56% with a 8.2% payout ratio, rated “safe” for safety.
How profitable is REGN?
In FY2025, REGENERON PHARMACEUTICALS, INC. had a net margin of 31.4% and a return on equity of 14.4%.
Is REGN overvalued or undervalued?
REGENERON PHARMACEUTICALS, INC. trades at about 19.2× trailing earnings — near its 10-year norm (10-year range 8.5×–46.7×, median 19.8×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for REGN?
The average Wall-Street price target for REGENERON PHARMACEUTICALS, INC. is $833.54, about 4.5% above the recent price, from 27 analysts (consensus: buy).
Is REGN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on REGENERON PHARMACEUTICALS, INC.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 14.7×, a dividend yield of 0.56%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.